NCT02436993View on ClinicalTrials.gov

Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

November 30, 2023

Study Completion Date

December 31, 2036

Conditions
Breast Carcinoma
Interventions
DRUG

Carboplatin

Area Under the Curve (AUC) 2 IV over 60 minutes weekly for 12 doses

DRUG

Paclitaxel

80 mg/m\^2 IV over 1-3 hours weekly for 12 doses

DRUG

Bevacizumab

10mg/kg IV over 90 or 60 or 30 minutes every other week for 5 doses

DRUG

Trastuzumab

4mg/kg induction, followed by weekly 2mg/kg IV-induction over 90 minutes, then weekly over 30-60 minutes for 12 doses

DRUG

Pertuzumab

840mg induction, followed by 420mg every 3 weeks IV-induction over 60 minutes, then every 3 weeks over 30-60 minutes for 4 doses

Trial Locations (1)

92868

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange

All Listed Sponsors
lead

University of California, Irvine

OTHER